Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Historical Holders from Q3 2018 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CRNX on Nasdaq
Shares outstanding
94,179,674
Price per share
$46.55
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
107,699,166
Total reported value
$4,485,877,349
% of total 13F portfolios
0%
Share change
+3,144,668
Value change
+$149,678,944
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
223
Price from insider filings
$55.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +46% $468,126,802 +$145,081,664 13,957,269 +45% FMR LLC 31 Mar 2025
VANGUARD GROUP INC 10% +2% $312,311,064 +$7,452,890 9,311,600 +2.4% The Vanguard Group 31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP 8.9% +45% $349,109,925 +$107,235,547 8,381,991 +44% Wellington Management Group LLP 30 Sep 2025
Farallon Capital Partners, L.P. 6% $165,377,881 5,625,098 Dapice Joshua J. 29 Aug 2025
As of 30 Sep 2025, Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) has 223 institutional shareholders filing 13F forms. They hold 107,699,166 shares. .

Top 25 institutional shareholders own 94% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 15% 14,187,498 +0.44% 0.03% $590,909,308
VANGUARD GROUP INC 9.7% 9,170,129 -0.93% 0.01% $381,935,873
WELLINGTON MANAGEMENT GROUP LLP 8.9% 8,381,991 +44% 0.06% $349,109,926
BlackRock, Inc. 8.1% 7,586,597 +2.3% 0.01% $315,981,777
Driehaus Capital Management LLC 6.9% 6,481,613 +1.3% 1.9% $269,959,181
FARALLON CAPITAL MANAGEMENT LLC 6.1% 5,770,098 +24% 1.4% $240,324,582
PRICE T ROWE ASSOCIATES INC /MD/ 5.6% 5,306,248 -5.1% 0.02% $221,006,000
EcoR1 Capital, LLC 4.6% 4,288,120 0% 8.6% $178,600,198
JANUS HENDERSON GROUP PLC 4.1% 3,858,791 +13% 0.07% $160,695,917
Paradigm Biocapital Advisors LP 2.7% 2,550,774 +8.8% 3.1% $106,239,737
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,278,830 +3% 0.01% $94,926,353
STATE STREET CORP 2.3% 2,207,707 -32% 0% $91,950,997
JENNISON ASSOCIATES LLC 2.2% 2,044,734 +2.9% 0.05% $85,163,170
Point72 Asset Management, L.P. 2.1% 2,003,333 +0.26% 0.18% $83,438,803
Siren, L.L.C. 1.8% 1,688,611 0% 2.8% $70,330,648
NOVO HOLDINGS A/S 1.7% 1,625,000 +4.8% 4.4% $67,681,250
Pictet Asset Management Holding SA 1.6% 1,465,262 +22% 0.06% $61,028,162
JPMORGAN CHASE & CO 1.3% 1,258,722 +279% 0% $52,425,771
AMERICAN CENTURY COMPANIES INC 1.2% 1,133,535 +34% 0.02% $47,211,782
ORBIMED ADVISORS LLC 1.2% 1,099,000 -4.4% 1.1% $45,773,350
First Light Asset Management, LLC 1% 941,516 +9% 3.7% $39,214,141
CITADEL ADVISORS LLC 0.94% 884,507 +35% 0.03% $36,839,717
Hood River Capital Management LLC 0.94% 883,004 -0.62% 0.43% $36,777,117
RTW INVESTMENTS, LP 0.93% 872,387 +87% 0.45% $36,334,919
GW&K Investment Management, LLC 0.9% 850,546 -12% 0.31% $35,425,000

Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 29,620 $1,378,822 -$1,544,582 4,655.22% 7
2025 Q3 107,699,166 $4,485,877,349 +$149,678,944 4,165% 223
2025 Q2 104,559,713 $3,007,383,972 +$75,026,428 2,876% 220
2025 Q1 101,790,251 $3,418,300,735 +$9,854,245 3,354% 224
2024 Q4 99,674,221 $5,096,189,681 +$758,216,412 5,113% 244
2024 Q3 84,507,337 $4,321,028,203 +$33,462,820 5,110% 232
2024 Q2 82,467,822 $3,693,699,265 +$92,226,194 4,479% 232
2024 Q1 80,359,899 $3,761,530,071 +$489,176,945 4,681% 202
2023 Q4 80,689 $2,870,914 -$1,386,175 3,558% 2
2023 Q3 68,511,875 $2,037,425,662 +$442,722,141 2,974% 169
2023 Q2 53,863,376 $970,580,866 -$14,285,261 1,802% 136
2023 Q1 55,022,720 $883,667,022 +$108,684 1,606% 126
2022 Q4 54,774,480 $1,002,337,337 -$29,154,494 1,830% 118
2022 Q3 51,383,891 $1,009,393,441 +$12,479,930 1,963.99% 113
2022 Q2 50,481,358 $941,464,132 +$94,025,834 1,865% 106
2022 Q1 45,457,476 $996,878,431 +$24,817,290 2,195% 111
2021 Q4 44,253,023 $1,255,973,441 +$251,348,520 2,841.01% 112
2021 Q3 33,618,331 $707,848,662 +$17,128,111 2,105% 91
2021 Q2 32,726,927 $616,934,642 +$43,330,866 1,884.98% 81
2021 Q1 30,663,471 $464,249,247 +$5,703,309 1,528% 77
2020 Q4 30,426,213 $429,299,885 -$4,585,138 1,411% 84
2020 Q3 30,337,604 $475,397,972 -$19,900,631 1,567% 70
2020 Q2 31,442,275 $545,926,663 +$188,615,966 1,751.99% 78
2020 Q1 20,679,259 $303,859,789 +$45,414,739 1,470.01% 54
2019 Q4 17,522,474 $439,633,847 -$5,476,517 2,509% 57
2019 Q3 15,234,699 $229,128,583 -$94,249,206 1,503.97% 60
2019 Q2 15,309,756 $382,744,098 +$30,946,837 2,500% 61
2019 Q1 17,728,104 $403,489,060 +$21,013,334 2,275.92% 61
2018 Q4 16,774,198 $503,053,000 +$19,132,463 2,998.97% 48
2018 Q3 16,164,854 $463,123,000 +$463,123,123 2,865% 48